ANYARA, TTS, Tumour Targeted Superantigens. Completed phase I.

The antibody element of the TTS is directed against a tumour specific antigen (5T4). Fused to the mab is a superantigen, a modified variant of Staphylococcal enterotoxin A (SEA), which attracts T cell

TTS have potent antitumour activity - stimulating the body's immune system to mount a targeted, local attack on malignant tumours. The fusion of two immunoreactive protein moieties in one designer molecule results in TTS drugs that are highly active in tumour tissue but have low potential for systemic toxicity.

The TTS substance, ANYARA (ABR-217620, naptumomab estafenatox) demonstrates potent antitumour activity in preclinical models of cancer. Potential indications for ANYARA include cancers of the lung, breast, pancreatic, kidney, gastrointestinal tract, prostate, ovary and cervix.  ANYARA has sucecessfully completed phase I studies in non small cell lunc cancer,  renal cell cancer  and pancreatic cancer.  Focus today is renal cell cancer  cancer.

Patents for TTS and ANYARA are expected to protect the candidate drugs for periods well beyond anticipated drug launch date.

Phase III

Active Biotech has several granted patents or patent applications covering TTS therapy and the various compounds investigated. The first set of patents covers the TTS concept in general, while the later applications cover novel superantigen variants. For ANYARA, a new patent application was filed in 2001.

Patent Case No. ABR-0840: European Patent No. 0444186, Patent Expiry Date 2010-09-14. Japan Patent No. 3147237, Patent Expiry Date 2010-09-14.

Patent Case No. ABR-0883: European Patent No. 0610179, Patent Expiry Date 2011-07-16. Japan Patent No. 3334130, Patent Expiry Date 2011-07-16. USA Patent No. 6,197,299, Patent Expiry Date 2011-07-16. USA Patent No. 5,858,363, Patent Expiry Date 2016-01-12.

Patent Case No. ABR-1492: European Patent No. 0766566, Patent Expiry Date 2015-06-07. Japan Patent Application No. 504251/96, Expected Patent Expiry date 2015-06-07. USA Patent Application No. 08/765,695, Expected Patent Expiry date 2015-06-07.

Patent Case No. ABR-1670: European Patent No. 835266, Expected Patent Expiry Date 2017-03-26. Japan Patent Application No. 535198/97, Expected Patent Expiry date 2017-03-26. USA Patent No. 6,514,498, Patent Expiry Date 2016-09-10.

Patent Case No. ABR-1776: European Patent Application No. 98935025.1, Expected Patent Expiry Date 2018-07-02. Japan Patent Application No. 2000-503871, Expected Patent Expiry Date 2018-07-02. USA Patent Application No. 09/463470, Expected Patent Expiry Date 2017-07-11.

Patent Case No. ABR-0032: European Patent Application No. 02746240.7, Expected Patent Expiry Date 2022-06-28. Japan Patent Application No. 2003-508382, Expected Patent Expiry Date 2022-06-28. USA Patent Application No. 09/900,766, Expected Patent Expiry Date 2021-07-06. Patent Case No. ABR-0052: International Patent Application No. PCT/EP2005/008815, Expected Patent Expiry Date 2024- 08-17. USA Patent Application No. 11/202,507, Expected Patent Expiry Date 2024-08-13.

Active Biotech seeks strategic liaisons and marketing partnership to support the on-going clinical development and commercialisation of Active Biotech AB TTS candidate and pipeline drugs